Search Result

Results for "

L-DOPA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) COMT (1) Dopamine Receptor (19) Dopamine Transporter (1) Drug Metabolite (2) Endogenous Metabolite (12) Glucosidase (1) Isotope-Labeled Compounds (1) mGluR (1) Opioid Receptor (2) Reactive Oxygen Species (1) Serotonin Transporter (1) Tyrosinase (4)
By Research Areas:	Cancer (5) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (18)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0304

*L-DOPA* Maximum Cited Publications 13 Publications Verification LevoDOPA; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; LevoDOPA ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-N0304A

L-DOPA sodium LevoDOPA sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

L-DOPA (Standard) LevoDOPA (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-116016

Etilevodopa L-DOPA ethyl ester; LevoDOPA ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-N0304S2

L-DOPA-13C 1 Publications Verification	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-132392S

L-DOPA-2,5,6-d3	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S

L-DOPA-d6 LevoDOPA-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304S1

L-DOPA-13C6 LevoDOPA-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-141647

*[18F]-Labeled L-dopa* precursor**	Dopamine Receptor	Others
[18F]-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa extracted from patent WO2014095739A1, example 8 .

HY-113468A

3-O-Methyldopa 3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA	Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-113468AS

3-O-Methyldopa-d3 3-Methoxy-L-tyrosine-d₃; 3-O-Methyl-L-DOPA-d₃	Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa-d₃ is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-113468AS1

3-O-Methyldopa-d3 hydrate 3-Methoxy-L-tyrosine-d₃ hydrate; 3-O-Methyl-L-DOPA-d₃ hydrate	Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-116750

6-Hydroxykaempferol	Tyrosinase	Others
6-Hydroxykaempferol, a flavonoid, is a competitive tyrosinase inhibitor with an IC₅₀ value of 124 μM. 6-Hydroxykaempferol has a K_i value of 148 μM relative to L-DOPA as a substrate and effectively inhibits the activity of the enzyme by binding to the active site of the enzyme .

HY-N10950

Vanicoside E	Dopamine Receptor	Cancer
Vanicoside E is an antioxidant and antitumor agent. Vanicoside E inhibits L-Tyrosine (HY-N0473) and *L-DOPA* (HY-N0304) with IC₅₀s of 45.23 μM and 189.96 μM, respectively .

HY-121939

6-Hydroxy-L-DOPA

Biochemical Assay Reagents Others

6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .

6-Hydroxy-L-DOPA	Biochemical Assay Reagents	Others
6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .

HY-149207

Tyrosinase-IN-11	Tyrosinase	Metabolic Disease
Tyrosinase-IN-11 is a potent tyrosinase inhibitor with IC₅₀s of 50 nM and 64 nM for L-tyrosinase and L-dopa, respectively. Tyrosinase-IN-11 has significant antioxidant activity and low cytotoxicity. Tyrosinase-IN-11 has the potential for skin hyperpigmentation research .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-15257

Mavoglurant 2 Publications Verification AFQ056	mGluR	Neurological Disease
Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC₅₀ of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W401531S

(R)-3-O-Methyldopa-d3	Dopamine Receptor Endogenous Metabolite	Neurological Disease
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride	Dopamine Receptor Endogenous Metabolite	Neurological Disease
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-106405

Nebicapone BIA 3-202	COMT	Metabolic Disease
Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .

HY-W037976

Tyrosinase-IN-22 5-Chloro-2-mercaptobenzimidazole	Reactive Oxygen Species Tyrosinase	Cancer
Tyrosinase-IN-22 (compound 4) is an inhibitor of tyrosinase substrates (L-tyrosine and L-dopa) with IC₅₀s of 60 nM and 30 nM, respectively. Tyrosinase-IN-22 also shows potent antioxidant and anti-melanogenic properties, thus can be used for relevant researches .

HY-N3237

Mulberrofuran H	Dopamine Receptor	Inflammation/Immunology
Mulberrofuran H is a 2-arylbenzofuran derivative from the cultivated mulberry tree (Morus lhou (ser.) Koidz.). Mulberrofuran H demonstrates potent inhibition against substrates L-tyrosine (IC₅₀=4.45 µM) and L-DOPA (IC₅₀=19.70 µM). Mulberrofuran H also shows potent anti-inflammatory and antioxidative activities .

HY-111242

SV 156	Dopamine Receptor	Neurological Disease
SV 156 is a potent and selective D2 dopamine receptor antagonist, with a K_i of 2.5 nM for hD2. SV 156 has approximately 40-fold binding selectivity for D2 dopamine receptors compared to the D3 receptor subtype. SV 156 can be used for L-DOPA (HY-N0304)-associated abnormal involuntary movements (AIMs) research .

HY-117512

UWA-101 hydrochloride	Dopamine Transporter Serotonin Transporter	Neurological Disease
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC₅₀ values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-N2278

Kushenol A 1 Publications Verification Leachianone E	Tyrosinase Glucosidase	Cancer
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC₅₀ and K_ivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC₅₀: 45 μM; K_i: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0304

*L-DOPA* Maximum Cited Publications 13 Publications Verification LevoDOPA; 3,4-Dihydroxyphenylalanine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-113468A

3-O-Methyldopa 3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA	Structural Classification Monophenols Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-N0304A

L-DOPA sodium LevoDOPA sodium; 3,4-Dihydroxyphenylalanine sodium	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

L-DOPA (Standard) LevoDOPA (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-116750

6-Hydroxykaempferol	Structural Classification Flavonols Flavonoids Trifolium repens Linn. Leguminosae Source classification Plants	Tyrosinase
6-Hydroxykaempferol, a flavonoid, is a competitive tyrosinase inhibitor with an IC₅₀ value of 124 μM. 6-Hydroxykaempferol has a K_i value of 148 μM relative to L-DOPA as a substrate and effectively inhibits the activity of the enzyme by binding to the active site of the enzyme .

HY-N10950

Vanicoside E	Structural Classification Polygonaceae Source classification Phenols Polyphenols Plants Persicaria hydropiper (L.) Spach	Dopamine Receptor
Vanicoside E is an antioxidant and antitumor agent. Vanicoside E inhibits L-Tyrosine (HY-N0473) and *L-DOPA* (HY-N0304) with IC₅₀s of 45.23 μM and 189.96 μM, respectively .

HY-N3237

Mulberrofuran H	Source classification Phenols Polyphenols Plants Moraceae Morus alba Linn.	Dopamine Receptor
Mulberrofuran H is a 2-arylbenzofuran derivative from the cultivated mulberry tree (Morus lhou (ser.) Koidz.). Mulberrofuran H demonstrates potent inhibition against substrates L-tyrosine (IC₅₀=4.45 µM) and L-DOPA (IC₅₀=19.70 µM). Mulberrofuran H also shows potent anti-inflammatory and antioxidative activities .

HY-N2278

Kushenol A 1 Publications Verification Leachianone E	Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Polyphenols Plants Sophora flavescens Aiton Disease Research Fields Cancer	Tyrosinase Glucosidase
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC₅₀ and K_ivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC₅₀: 45 μM; K_i: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .

Cat. No.	Product Name	Chemical Structure

HY-N0304S2

L-DOPA-13C 1 Publications Verification
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-132392S

L-DOPA-2,5,6-d3
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S

L-DOPA-d6
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-113468AS

3-O-Methyldopa-d3
3-O-Methyldopa-d₃ is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-N0304S1

L-DOPA-13C6
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-113468AS1

3-O-Methyldopa-d3 hydrate
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-W401531S

(R)-3-O-Methyldopa-d3
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

L-DOPA

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products